Acquired Von Willebrand Syndrome: A Review
Published: 2023-08-16
Page: 165-178
Issue: 2023 - Volume 6 [Issue 2]
Danyal Ahmad Ghani *
Department of Haematology and Oncology, Shifa International Hospital, Islamabad, Pakistan.
Muhammad Ayaz Younas Mir
Department of Haematology and Oncology, Shifa International Hospital, Islamabad, Pakistan.
*Author to whom correspondence should be addressed.
Abstract
Acquired von Willebrand Disease (AvWD) is an uncommon bleeding disorder resulting from the development of decreased quantities of circulating functional von Willebrand factor (vWF). The condition may occur due to a number of pathogenic mechanisms, and is invariably associated with an underlying disorder such as congenital heart disease, neoplasms, and autoimmunity or with the use of certain drugs. While its manifestations are similar to that of inherited von Willebrand disease (vWD) in terms of clinical signs and laboratory results, it differs in that the patient lacks a personal or family history of bleeding and presents later in life. Management of the disorder is based on treatment of the underlying condition, which usually results in resolution of the bleeding diathesis. Acute hemorrhage usually requires vWF concentrates and in some cases immunosuppression. Other options involve use of Intravenous Immunoglobulins (IVIg) or plasmapheresis. Recently, immunotherapies and novel agents such as Emicizumab, Lenalidomide and Rtiuximab have been tried as off-label options.
Keywords: Acquired von Willebrand syndrome, clinical presentation, diagnosis, hemorrhagic diathesis, management, pathophysiology
How to Cite
Downloads
References
Kozlov S, Okhota S, Avtaeva Y, Melnikov I, Matroze E, Gabbasov Z. Von Willebrand factor in diagnostics and treatment of cardiovascular disease: Recent advances and prospects. Front Cardiovasc Med. 2022;9:1038030.
DOI: 10.3389/fcvm.2022.1038030
Cortes GA, Moore MJ, El-Nakeep S. Physiology, Von Willebrand factor. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available:https://www.ncbi.nlm.nih.gov/books/NBK559062/.
Sabih A, Babiker HM. Von Willebrand disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available:https://www.ncbi.nlm.nih.gov/books/NBK459222/.
Franchini M, Mannucci PM. Acquired von Willebrand syndrome: Focused for hematologists. Haematologica. 2020;105(8):2032-2037. DOI: 10.3324/haematol.2020.255117
Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand disease. Mayo Clin Proc. 2002;77(2):181-7.
DOI: 10.4065/77.2.181
Federici AB. Acquired von Willebrand syndrome: An underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol. 2006;43(1 Suppl 1):S48-58.
DOI: 10.1053/j.seminhematol.2005.11.003.
Leebeek FW. New developments in diagnosis and management of acquired hemophilia and acquired von Willebrand syndrome. Hemasphere. 2021;5(6):e586. DOI: 10.1097/HS9.0000000000000586
Mital A. Acquired von Willebrand syndrome. Adv Clin Exp Med. 2016;25(6):1337-1344. DOI: 10.17219/acem/64942
Charlebois J, Rivard GÉ, St-Louis J. Management of acquired von Willebrand syndrome. Transfus Apher Sci. 2018;57(6):721-723. DOI: 10.1016/j.transci.2018.10.012
Simone JV, Cornet JA, Abildgaard CF. Acquired von Willebrand's syndrome in systemic lupus erythematosus. Blood. 1968;31(6):806-12.
Langer AL, Connell NT. Acquired von Willebrand syndrome. Hematol Oncol Clin North Am. 2021;35(6):1103-1116.
DOI: 10.1016/j.hoc.2021.07.005
Shetty S, Kasatkar P, Ghosh K. Pathophysiology of acquired von Willebrand disease: A concise review. Eur J Haematol. 2011;87(2):99-106. DOI: 10.1111/j.1600-0609.2011.01636.x
Haberichter SL. von Willebrand factor propeptide: Biology and clinical utility. Blood. 2015;126(15):1753-61.
DOI: 10.1182/blood-2015-04-512731
Mojzisch A, Brehm MA. The manifold cellular functions of von Willebrand factor. Cells. 2021;10(9):2351.
DOI: 10.3390/cells10092351
Michels A, Swystun LL, Mewburn J, Albánez S, Lillicrap D. Investigating von Willebrand factor pathophysiology using a flow chamber model of von Willebrand factor-platelet string formation. J Vis Exp. 2017;(126):55917.
DOI: 10.3791/55917
Peyvandi F, Garagiola I, Baronciani L. Role of von Willebrand factor in the haemostasis. Blood Transfus. 2011;9 Suppl 2(Suppl 2):s3-8. DOI: 10.2450/2011.002S
Furlan M. Von Willebrand factor: Molecular size and functional activity. Ann Hematol. 1996;72(6):341-8.
DOI: 10.1007/s002770050184
Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424.
DOI: 10.1146/annurev.biochem.67.1.395
Bryckaert M, Rosa JP, Denis CV, Lenting PJ. Of von Willebrand factor and platelets. Cell Mol Life Sci. 2015;72(2):307-26. DOI: 10.1007/s00018-014-1743-8
Ruggeri ZM, Mendolicchio GL. Interaction of von Willebrand factor with platelets and the vessel wall. Hamostaseologie. 2015;35(3):211-24. DOI: 10.5482/HAMO-14-12-0081
Bharati KP, Prashanth UR. Von Willebrand disease: An overview. Indian J Pharm Sci. 2011;73(1):7-16.
DOI: 10.4103/0250-474X.89751
Federici AB. The factor VIII/von Willebrand factor complex: Basic and clinical issues. Haematologica. 2003;88(6):EREP02.
Fuller JR, Knockenhauer KE, Leksa NC, Peters RT, Batchelor JD. Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy. Blood. 2021;137(21):2970-2980.
DOI: 10.1182/blood.2020009197
Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and ADAMTS13 deficiency: A unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost. 2015;113(4):708-18. DOI: 10.1160/TH14-09-0731.
Raife TJ, Cao W, Atkinson BS, Bedell B, Montgomery RR, Lentz SR, Johnson GF, Zheng XL. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood. 2009;114(8):1666-74.
DOI: 10.1182/blood-2009-01-195461
Chen J, Chung DW. Inflammation, von Willebrand factor, and ADAMTS13. Blood. 2018;132(2):141-147.
DOI: 10.1182/blood-2018-02-769000
Drenko P, Přenosilová P, Lavičková A. Acquired von Willebrand Syndrome (AvWS). Vnitr Lek. 2022;68(E-4):16-19.
Wolfe Z, Lash B. Acquired von Willebrand syndrome in IgM monoclonal gammopathy as the presentation of lymphoplasmacytic lymphoma. Case Rep Hematol. 2017; 2017:9862620.
DOI: 10.1155/2017/9862620
Gkalea V, Fotiou D, Dimopoulos MA, Kastritis E. Monoclonal gammopathy of thrombotic significance. Cancers (Basel). 2023;15(2):480. DOI: 10.3390/cancers15020480
Dicke C, Schneppenheim S, Holstein K, Spath B, Bokemeyer C, Dittmer R, Budde U, Langer F. Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias. Ann Hematol. 2016;95(6):945-57. DOI: 10.1007/s00277-016-2650-x.
Tiede A. Diagnosis and treatment of acquired von Willebrand syndrome. Thromb Res. 2012;130 Suppl 2:S2-6.
DOI: 10.1016/S0049-3848(13)70003-3
Mehta R, Athar M, Girgis S, Hassan A, Becker RC. Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: A state of the art review for clinicians. J Thromb Thrombolysis. 2019; 48(1):14-26.
DOI: 10.1007/s11239-019-01849-2
Manfredi E, van Zaane B, Gerdes VE, Brandjes DP, Squizzato A. Hypothyroidism and acquired von Willebrand's syndrome: a systematic review. Haemophilia. 2008; 14(3):423-33.
DOI: 10.1111/j.1365-2516.2007.01642.x.
Zhussupbekov M, Méndez Rojano R, Wu WT, Massoudi M, Antaki JF. A Continuum Model for the Unfolding of von Willebrand Factor. Ann Biomed Eng. 2021;49(9):2646-2658. DOI: 10.1007/s10439-021-02845-5
Zheng XL. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med. 2015;66:211-25. DOI: 10.1146/annurev-med-061813-013241
Owari M, Harada-Shirado K, Togawa R, Fukatsu M, Sato Y, Fukuchi K, Endo M, Takahashi H, Kimura S, Osaki T, Souri M, Ichinose A, Shibata Y, Hashimoto Y, Ikezoe T. Acquired von Willebrand syndrome in a patient with multiple comorbidities, including MALT lymphoma with IgA monoclonal gammopathy and hyperviscosity syndrome. Intern Med. 2023;62(4):605-611. DOI: 10.2169/internalmedicine.9815-22
van Genderen PJ, Michiels JJ. Acquired von Willebrand disease. Baillieres Clin Haematol. 1998;11(2):319-30.
DOI: 10.1016/s0950-3536(98)80051-6
Mohri H. Acquired von Willebrand syndrome: Its pathophysiology, laboratory features and management. J Thromb Thrombolysis. 2003;15(3):141-9. DOI:10.1023/B:THRO.0000011369.70824.e6
Tefferi A, Hanson CA, Kurtin PJ, Katzmann JA, Dalton RJ, Nichols WL. Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells. Br J Haematol. 1997;96(4):850-3.
DOI:10.1046/j.1365-2141.1997.d01-2088.x
Mayne ES, Tait M, Jacobson BF, Pillay E, Louw SJ. Combination of Acquired Von Willebrand Syndrome (AVWS) and Glanzmann thrombasthenia in Monoclonal Gammopathy of Uncertain Significance (MGUS), a case report. Thromb J. 2018;16:30. DOI: 10.1186/s12959-018-0184-2
Yee MEM, Batsuli G, Chonat S, Park S. Thrombocytosis with acquired von Willebrand disease in an adolescent with sickle cell disease. Clin Case Rep. 2020;9(1):457-460. DOI: 10.1002/ccr3.3556
Innocenti I, Morelli F, Autore F, Tomasso A, Corbingi A, Bellesi S, Za T, De Stefano V, Laurenti L. Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax. Leuk Lymphoma. 2019;60(12): 3078-3080. DOI: 10.1080/10428194.2019.1612063
Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, Kodama F, Okubo T. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood. 1998;91(10):3623-9.
Djunic I, Elezovic I, Ilic V, Tomin D, Suvajdzic-Vukovic N, Bila J, Antic D, Vidovic A, Milosevic-Jovcic N. Acquired von Willebrand syndrome in multiple myeloma. Hematology. 2011;16(4):209-12.
DOI: 10.1179/102453311X12953015767617
Mohri H, Tanabe J, Ohtsuka M, Yoshida M, Motomura S, Nishida S, Fujimura Y, Okubo T. Acquired von Willebrand disease associated with multiple myeloma; characterization of an inhibitor to von Willebrand factor. Blood Coagul Fibrinolysis. 1995;6(6):561-6. DOI: 10.1097/00001721-199509000-00010
Hivert B, Caron C, Petit S, Charpy C, Fankam-Siaka C, Lecocq S, Zawadzki C, Susen S, Rusu M, Duhamel A, Tournilhac O, Goudemand J, Morel P. Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. Blood. 2012;120(16):3214-21.
DOI: 10.1182/blood-2011-11-388256
Vanderschueren S, Mylle M, Dierickx D, Delforge M, Verhamme P, Peerlinck K, Meersseman W, Knockaert DC. Monoclonal gammopathy of undetermined significance: Significant beyond hematology. Mayo Clin Proc. 2009;84(9) :842-5. DOI: 10.1016/S0025-6196(11)60495-3
Galletta E, Galvanin F, Bertomoro A, Daidone V, Casonato A. Acquired von Willebrand syndrome in patients with monoclonal gammopathy of undetermined significance investigated using a mechanistic approach. Blood Transfus. 2023;21(1):74-82. DOI: 10.2450/2021.0121-21
Coppes MJ, Zandvoort SW, Sparling CR, Poon AO, Weitzman S, Blanchette VS. Acquired von Willebrand disease in Wilms' tumor patients. J Clin Oncol. 1992;10(3): 422-7. DOI: 10.1200/JCO.1992.10.3.422
Fosbury E, Szychot E, Slater O, Mathias M, Sibson K. An 11-year experience of acquired von Willebrand syndrome in children diagnosed with Wilms tumour in a tertiary referral centre. Pediatr Blood Cancer. 2017;64(3).
DOI: 10.1002/pbc.26246.
Binnetoğlu FK, Babaoğlu K, Filiz ŞG, Zengin E, Altun G, Kılıç SÇ, Sarper N. Acquired von Willebrand syndrome in children with aortic and pulmonary stenosis. Cardiovasc J Afr. 2016;27(4): 222-227.
DOI: 10.5830/CVJA-2015-093
Waldow HC, Westhoff-Bleck M, Widera C, Templin C, von Depka M. Acquired von Willebrand syndrome in adult patients with congenital heart disease. Int J Cardiol. 2014;176(3):739-45. DOI: 10.1016/j.ijcard.2014.07.104
Nascimbene A, Neelamegham S, Frazier OH, Moake JL, Dong JF. Acquired von Willebrand syndrome associated with left ventricular assist device. Blood. 2016;127(25):3133-41. DOI: 10.1182/blood-2015-10-636480
Meyer AL, Malehsa D, Budde U, Bara C, Haverich A, Strueber M. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail. 2014;2(2):141-5.
DOI: 10.1016/j.jchf.2013.10.008
Kalbhenn J, Schmidt R, Nakamura L, Schelling J, Rosenfelder S, Zieger B. Early diagnosis of acquired von Willebrand Syndrome (AVWS) is elementary for clinical practice in patients treated with ECMO therapy. J Atheroscler Thromb. 2015;22(3):265-71. DOI: 10.5551/jat.27268
Mital A, Prejzner W, Bieniaszewska M, Hellmann A. Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: A retrospective analysis of 170 consecutive patients. Pol Arch Med Wewn. 2015;125(12):914-20. DOI: 10.20452/pamw.3211
Rottenstreich A, Kleinstern G, Krichevsky S, Varon D, Lavie D, Kalish Y. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. Eur J Intern Med. 2017;41:49-54. DOI: 10.1016/j.ejim.2016.11.011
Song IC, Kang S, Lee MW, Ryu H, Lee HJ, Yun HJ, Jo DY. Acquired von willebrand syndrome in patients with philadelphia-negative myeloproliferative neoplasm. Blood Res. 2023;58(1):42-50.
DOI: 10.5045/br.2023.2022218
Jain A. A rare case of chronic myeloid leukemia with acquired von Willebrand disease presenting as subdural hematoma. J Cancer Res Ther. 2015; 11(4):1022. DOI: 10.4103/0973-1482.146136
Mital A, Prejzner W, Hellmann A. Acquired von Willebrand syndrome during the course of myelofibrosis: Analysis of 32 cases. Adv Clin Exp Med. 2015;24(6): 1001-6. DOI: 10.17219/acem/52361
Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, Meyer D, Rodeghiero F, Sadler JE; Subcommittee on von Willebrand factor. Acquired von Willebrand syndrome: Data from an international registry. Thromb Haemost. 2000;84(2):345-9.
Stuijver DJ, Piantanida E, van Zaane B, Galli L, Romualdi E, Tanda ML, Meijers JC, Büller HR, Gerdes VE, Squizzato A. Acquired von Willebrand syndrome in patients with overt hypothyroidism: A prospective cohort study. Haemophilia. 2014;20(3):326-32. DOI: 10.1111/hae.12275
Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand's syndrome: A single institution experience. Am J Hematol. 2003;72(4):243-7. DOI: 10.1002/ajh.10298
Sandrock-Lang K, Glonnegger H, Zieger B. Acquired von Willebrand syndrome in children. Hamostaseologie. 2022;42(2): 117-122. DOI: 10.1055/a-1790-6156
Fressinaud E, Meyer D. International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost. 1993;70(3):546.
Selvam S, James P. Angiodysplasia in von Willebrand disease: Understanding the clinical and basic science. Semin Thromb Hemost. 2017;43(6):572-580. DOI: 10.1055/s-0037-1599145
Little JW, Falace DA, Miller CS, Rhodus NL. Partial thromboplastin time, acquired bleeding and hypercoagulable disorders. In: Little and Falace's Dental Management of the Medically Compromised Patient. Mosby. 2013;409-436.
Available:https://www.sciencedirect.com/science/article/pii/B9780323080286000245/
Nitu-Whalley IC, Lee CA. Acquired von Willebrand syndrome--report of 10 cases and review of the literature. Haemophilia. 1999;5(5):318-26. DOI: 10.1046/j.1365-2516.1999.00340.x
Favaloro EJ. Utility of the platelet function analyser (PFA-100/200) for exclusion or detection of von Willebrand disease: A study 22 years in the making. Thromb Res. 2020;188:17-24. DOI: 10.1016/j.thromres.2020.01.029
O'Donnell JS. Low VWF: insights into pathogenesis, diagnosis, and clinical management. Blood Adv. 2020;4(13):3191-3199. DOI: 10.1182/bloodadvances.2020002038
Bellissimo DB, Christopherson PA, Flood VH, Gill JC, Friedman KD, Haberichter SL, Shapiro AD, Abshire TC, Leissinger C, Hoots WK, Lusher JM, Ragni MV, Montgomery RR. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood. 2012;119(9):2135-40.
DOI: 10.1182/blood-2011-10-384610
Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69(6):1691-5.
Flood VH. Perils, problems, and progress in laboratory diagnosis of von Willebrand disease. Semin Thromb Hemost. 2014;40(1):41-8.
DOI: 10.1055/s-0033-1363166
Kallas A, Talpsep T. The von Willebrand factor collagen-binding activity assay: Clinical application. Ann Hematol. 2001;80(8):466-71.
DOI: 10.1007/s002770100329
Thomazini CM, Soares RPS, da Rocha TRF, Sachetto ATA, Santoro ML. Optimization of von Willebrand factor multimer analysis in vertical mini-gel electrophoresis systems: A rapid procedure. Thromb Res. 2019;175:76-83.
DOI: 10.1016/j.thromres.2019.01.018.
Lee A, Sinclair G, Valentine K, James P, Poon MC. Acquired von Willebrand syndrome: von Willebrand factor propeptide to von Willebrand factor antigen ratio predicts remission status. Blood. 2014;124(5):e1-3.
DOI: 10.1182/blood-2014-02-557132
Federici AB, Budde U, Castaman G, Rand JH, Tiede A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: A 2013 update. Semin Thromb Hemost. 2013;39 (2):191-201.
DOI: 10.1055/s-0033-1334867
van Genderen PJ, Vink T, Michiels JJ, van 't Veer MB, Sixma JJ, van Vliet HH. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood. 1994;84(10):3378-84.
Rinder MR, Richard RE, Rinder HM. Acquired von Willebrand's disease: A concise review. Am J Hematol. 1997;54(2): 139-45.
DOI:10.1002/(sici)1096-8652(199702)54: 2<139::aid-ajh7>3.0.co;2-y.
Franchi F, Biguzzi E, Stufano F, Siboni SM, Baronciani L, Peyvandi F. A two-step approach (Enzyme-linked immunosorbent assay and confirmation assay) to detect antibodies against von Willebrand factor in patients with acquired von Willebrand Syndrome. Thromb Res. 2014;134(6):1316-22.
DOI: 10.1016/j.thromres.2014.09.020
Tuohy E, Litt E, Alikhan R. Treatment of patients with von Willebrand disease. J Blood Med. 2011;2:49-57.
DOI: 10.2147/JBM.S9890
Abou-Ismail MY, Rodgers GM, Bray PF, Lim MY. Acquired von Willebrand syndrome in monoclonal gammopathy - A scoping review on hemostatic management. Res Pract Thromb Haemost. 2021;5(2):356-365.
DOI: 10.1002/rth2.12481
Dane KE, Lindsley JP, Kickler T, Streiff MB, Moliterno A, Yui J, Naik R, Chaturvedi S. Continuous-infusion von Willebrand factor concentrate is effective for the management of acquired von Willebrand disease. Blood Adv. 2021;5(14):2813-2816.
DOI: 10.1182/bloodadvances.2021004843
Levy JH, Koster A, Quinones QJ, Milling TJ, Key NS. Antifibrinolytic therapy and perioperative considerations. Anesthesiology. 2018;128(3):657-670.
DOI: 10.1097/ALN.0000000000001997
Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis. 1998;9 Suppl 1:S15-20.
Giansily-Blaizot M, Schved JF. Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date. Ther Adv Hematol. 2017; 8(12):345-352.
DOI: 10.1177/2040620717737701
Federici AB, Rossi V, Sacchi E, Franchini M. Are intravenous immunoglobulins really inappropriate in acquired von Willebrand syndrome? Blood Transfus. 2012;10(3): 402-3. DOI: 10.2450/2011.0091-11
Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood. 1998;92(8):2707-11.
Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood. 2011;117 (25):6777-85. DOI: 10.1182/blood-2010-11-297580
Erratum: Gill JC, Castaman G, Windyga J, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038-2046.
DOI: 10.1182/blood-2016-04-711259.
Kurahashi H, Kawabata Y, Michishita Y, Kitabayashi A, Kobayashi T, Kitadate A, Takahashi N. [Durable remission attained with rituximab therapy in a patient with acquired von Willebrand syndrome associated with CD20-positive lymphoproliferative disorder]. Rinsho Ketsueki. 2018;59(4):420-425.
DOI: 10.11406/rinketsu.59.420.
Lavin M, Brophy TM, Rawley O, O'Sullivan JM, Hayden PJ, Browne PV, Ryan K, O'Connell N, O'Donnell JS. Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. J Thromb Haemost. 2016;14(6):1200-5. DOI: 10.1111/jth.13317
Green A, Shen YP, Nelson AT, Sarode R, Ibrahim IF, Cao J, Afraz S, Yates SG. Successful use of lenalidomide to treat refractory acquired von Willebrand disease associated with monoclonal gammopathy. Ann Hematol. 2022;101(12):2627-2631. DOI: 10.1007/s00277-022-04991-9
Thomas VM, Abou-Ismail MY, Lim MY. Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature. Haemophilia. 2022;28(1):4-17.
DOI: 10.1111/hae.14450
Biguzzi E, Siboni SM, Peyvandi F. How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease. Blood. 2020;136(10):1125-1133. DOI: 10.1182/blood.2019003702
Yee J, Kaide CG. Emergency reversal of anticoagulation. West J Emerg Med. 2019;20(5):770-783.
DOI: 10.5811/westjem.2018.5.38235
McCarty TS, Shah AD. Desmopressin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
Available:https://www.ncbi.nlm.nih.gov/books/NBK554582/
Waheed W, et al. Cerebral venous thrombosis associated with thyrotoxicosis, the use of desmopressin and elevated factor VIII/von Willebrand factor. BMJ Case Rep. 2016;2016:bcr2016216584.
DOI: 10.1136/bcr-2016-216584
Tan HH, et al. Successful treatment with thalidomide for a patient with recurrent gastrointestinal bleeding due to angiodysplasia diagnosed by capsule endoscopy. J Dig Dis. 2013;14(3):153-5.
DOI: 10.1111/1751-2980.12009
Franchini M, Seidizadeh O, Mannucci PM. Prophylactic management of patients with von Willebrand disease. Ther Adv Hematol. 2021;12:20406207211064064. DOI: 10.1177/20406207211064064